Overview

Salvage Treatment With Lenalidomide and Dexamethaosne (LEN-DEX) in Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL)

Status:
Completed

Trial end date:
2011-08-01

Target enrollment:

Participant gender:

Summary

This is a prospective, multicenter phase II trial designed to evaluate the safety and activity of the combination of Lenalidomide (Len) and Dexamethasone (Dex) in patients with relapsed/refractory mantle cell lymphoma (MCL).

Phase:

Phase 2

Details

Lead Sponsor:

Fondazione Italiana Linfomi ONLUS

Collaborator:

Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte

Treatments:

BB 1101
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Lenalidomide
Thalidomide